NEOG

Neogen is a real diagnostics business — $895M revenue, 47.1% gross margin, $58.2M of operating cash flow — but the FY2025 filing reads as the unwinding of an overpriced acquisition, not a stabilizing one. Management took a $1,059.3M goodwill impairment (the entire source of the -$1.06B operating loss and -$5.03 EPS), an admission that the 3M Food Safety deal that roughly doubled revenue from $527M (FY2022) to $822M+ is worth far less than paid. Strip the non-cash charge and the company is only at operating breakeven, yet it still owes $71.6M of annual interest expense against $875M of long-term debt and just $129M of cash — interest alone now exceeds underlying operating profit. Revenue fell 3.2% YoY (a real ~$1.4M core decline plus FX and discontinued lines), gross margin compressed from 50.2% to 47.1% on inventory write-offs and lingering ERP-implementation costs, and the genomics service line is shrinking on customer insourcing and attrition.

The disqualifying item is governance: the Certifying Officers concluded disclosure controls 'were not effective as of such date due to material weaknesses in internal control over financial reporting.' For a company already missing on every operating line, unreliable financial reporting raises the cost of trusting any single number and is exactly the 'avoid'-adjacent risk that argues against buying the dip. Free cash flow is negative — $58.2M operating cash against $105M of capex — so the balance sheet is not self-funding its own investment, and retained earnings have swung to -$536M.